$HUM

UBS downgraded PG&E (PCG) to Neutral, cutting its price target by 26% due to regulatory risks and financial pressures. HSBC downgraded Netflix (NFLX) to Hold, citing competition and rising costs. Rothschild Redburn downgraded Moderna (MRNA) to Sell, targeting a 58% downside. HSBC downgraded BMW (BMW) to Hold, citing worsening China sales. Barclays upgraded Humana (HUM) to Overweight, forecasting a 29% upside.

Humana's stock rose 6.2% after Barclays upgraded it to Overweight and raised its price target to $515. The firm cited confidence in Humana's turnaround and Medicare Advantage improvements. Management reaffirmed 2026 EPS guidance of at least $9.00. The S&P 500, Dow Jones, and Nasdaq also saw modest gains.

Humana Inc. (HUM) shares rose 6% after Barclays upgraded the stock to overweight, citing optimism about Medicare Star ratings. Analyst Andrew Mok expects the H5216 contract, covering 2.4 million lives, to be upgraded, which could add $1.5B in EBIT and $9 in EPS. Barclays raised its price target to $515 from $407.

Analysts made multiple rating changes: Wells Fargo initiated Johnson Controls (JCI) as overweight, UBS initiated Chemed (CHE) as buy, Mizuho reiterated SpaceX as outperform, Barclays initiated Ligand Pharmaceuticals (LGND) as overweight, Seaport reiterated Nvidia (NVDA) as sell, UBS upgraded Stem (STEM) to buy, HSBC upgraded BP (BP) to buy, Bernstein initiated CF Industries (CF) as outperform, Bank of America reiterated AMD (AMD) as buy, Bernstein reiterated Apple (AAPL) as outperform, JPMorgan…

Medicare Advantage plans in Florida are reducing supplemental benefits for 2027, including grocery allowances, dental maximums, and gym memberships, while maintaining $0 premiums. Humana and UnitedHealthcare are cutting plans and benefits due to flat payment rates and rising medical costs. Enrollees have until December 7 to compare options, with changes affecting 5 million Floridians.

Louisiana's Department of Health proposed $16.1B in contracts for four remaining Medicaid insurers: Aetna, AmeriHealth, Humana, and Louisiana Healthcare. This follows the exit of UnitedHealthcare and Elevance Health's Healthy Blue, affecting 580K enrollees. The contracts range from $3.2B to $5.8B annually, pending legislative approval.

Humana expects 25% Medicare Advantage membership growth by 2026, plans to exit unprofitable markets. Stock outperforms Dow but lags rivals like Centene. Analysts give 'Moderate Buy' rating, $421.35 mean price target, 4.5% upside.

Humana (HUM) and HealthStream (HSTM) partnered to expand caregiver training. Humana reported Q2 2026 adjusted EPS of $7.61, lowering FY GAAP EPS guidance to $6.52. HealthStream saw Q2 revenue rise 12.5% to $83.7M, with net income up 23.8%. Humana faces regulatory pressures, while HealthStream benefits from strong margins and a debt-free balance sheet.

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

Humana (HUM) is ending Medicare Advantage plans for about 600,000 members in 2027. Affected members will revert to Original Medicare, which has a $1,736 Part A deductible and no annual out-of-pocket cap. They must act by December 31 to secure new coverage or face gaps in drug coverage and potential penalties. Medigap enrollment has a limited window for guaranteed issue rights.